Pharmacokinetics of a Fixed-Dose Combination of Atorvastatin and Metformin Extended Release versus Concurrent Administration of Individual Formulations

Background: Type 2 diabetes mellitus is associated with a 2- to 4-fold increased risk of coronary heart disease (CHD). Combined therapy with an antihyperglycaemic agent and an HMG-CoA reductase inhibitor (statin) is indicated for the treatment of diabetic patients at risk of CHD. Patients with type...

Full description

Saved in:
Bibliographic Details
Published in:Clinical drug investigation 2011-12, Vol.31 (12), p.853
Main Authors: Kandhwal, Kirti, Dey, Surajit, Nazarudheen, Shabana, Arora, Rachna, Reyar, Simrit, Thudi, Nageshwar R, Monif, Tausif, Singh, Manoj K, Rao, Shireen
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Type 2 diabetes mellitus is associated with a 2- to 4-fold increased risk of coronary heart disease (CHD). Combined therapy with an antihyperglycaemic agent and an HMG-CoA reductase inhibitor (statin) is indicated for the treatment of diabetic patients at risk of CHD. Patients with type 2 diabetes are generally considered to be at equivalent cardiovascular disease risk to patients with established CHD, and should have low-density lipoprotein (LDL) cholesterol levels reduced to
ISSN:1173-2563
1179-1918
DOI:10.2165/11592920-000000000-00000